TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

About this update from Tg Therapeutics, Inc.

[{"type":"text","content":"NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each of the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share additional exploratory analyses from the ULTIMATE I & II Phase 3 trials at the ACTRIMS conference this week. We believe these data further support the unique attributes of BRIUMVI which is now commercially available, and we look forward to continuing to share additional analyses throughout the year.” PRESENTATIONSPoster Presentation: Early, Transient Shift in Hematologic Parameters Observed with Ublituximab in the ULTIMATE I and II Phase 3 Studies Lead Author: Peiqing Qian, MD, Swedish Neuroscience Institute, Seattle, WA Poster Presentation: Onset and Maintenance of No Evidence of Disease Activity with Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants with Relapsing Multiple Sclerosis Lead Author: Enrique Alvarez, MD, University of Colorado, Aurora, CO The above presentations are also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm. ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous ...

More updates from Tg Therapeutics, Inc.